LMR Partners LLP
Institutional investor · Portfolio as of Q2 2023
Top Holdings879 positions
Invesco QQQ Trust, Series 1 UNIT SER 1 | 2.1M | $791.6M | 8.8% | — | — | — | New — |
State Street Spdr S&p 500 Etf Trust TR UNIT | 1.5M | $648.5M | 7.2% | — | — | — | New — |
Apple Inc. | 2.7M | $532.8M | 5.9% | — | — | — | New — |
Apple Inc. | 1.2M | $228.6M | 2.5% | — | — | — | New — |
iShares Trust RUSSELL 2000 ETF | 1.2M | $215.4M | 2.4% | — | — | — | New — |
| 69.9M | $128.5M | 1.4% | — | — | 2 qtrssince 2023-Q1 | Unchanged 0 | |
HORIZON THERAPEUTICS PUB L | 1.1M | $117.2M | 1.3% | — | — | 5 qtrssince 2022-Q2 | Increased 63 |
State Street Spdr S&p 500 Etf Trust TR UNIT | 227,000 | $100.6M | 1.1% | — | — | — | New — |
iShares Trust RUSSELL 2000 ETF | 501,000 | $93.8M | 1.0% | — | — | — | New — |
CARNIVAL CORP | 4.7M | $87.6M | 1.0% | — | — | — | Increased — |
ACTIVISION BLIZZARD INC | 1M | $86.1M | 1.0% | — | — | 4 qtrssince 2022-Q3 | Increased 68 |
Eli Lilly & Co. | 180,800 | $84.8M | 0.9% | — | — | — | New — |
NVIDIA Corp. | 196,693 | $83.2M | 0.9% | $24.29 | +73.65% | 3 qtrssince 2022-Q4 | Decreased 0 |
LPL FINL HLDGS INC | 378,991 | $82.4M | 0.9% | $201.26 | +6.58% | 8 qtrssince 2021-Q3 | Increased 57 |
IVERIC BIO INC | 2M | $79.6M | 0.9% | — | — | 1 qtr | New 58 |
Tesla Inc | 300,000 | $78.5M | 0.9% | — | — | — | New — |
TRIPADVISOR INC | 4.7M | $76.9M | 0.9% | — | — | — | Increased — |
Invesco QQQ Trust, Series 1 UNIT SER 1 | 200,000 | $73.9M | 0.8% | — | — | — | New — |
SELECT SECTOR SPDR TR | 423,800 | $73.7M | 0.8% | — | — | — | New — |
ACTIVISION BLIZZARD INC | 851,400 | $71.8M | 0.8% | — | — | — | New — |
LMR Partners LLP manages $9B across 879 positions as of Q2 2023. Top holdings: QQQ puts (8.8%), SPY puts (7.2%), AAPL calls (5.9%). Fund DNA: Diversified Scout. HoldingsIntel Score: 1.5/5.0.
Active quarter - 163 new positions, 401 exits, 129 increased. Top move: ATVI (INCREASED, conviction 68). Portfolio: $9.0B across 879 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR